TSS
SONN

Two Sigma Securities’s Sonnet BioTherapeutics SONN Stock Holding History

Two Sigma Securities’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-387
Closed -$33.4K – 3429
2023
Q2 		$33.4K Buy
+387
New +$27.3K ﹤0.01% 2447
2023
Q1 		– Sell
-102
Closed -$20.7K – 3224
2022
Q4 		$20.7K Buy
102
+34
+50% +$7.44K ﹤0.01% 2272
2022
Q3 		$18K Buy
68
+63
+1,260% +$36.8K ﹤0.01% 2313
2022
Q2 		$4K Sell
5
-43
-90% -$30.8K ﹤0.01% 2120
2022
Q1 		$45K Buy
48
+35
+269% +$29.6K ﹤0.01% 1891
2021
Q4 		$13K Sell
13
-2
-13% -$2.87K ﹤0.01% 1454
2021
Q3 		$22K Buy
+15
New +$33.4K ﹤0.01% 1457
2016
Q1 		– Hold
0
– -$16K – 388
2015
Q4 		– Hold
0
– – – 212
2015
Q3 		– Hold
0
– – – 189

Other funds holding SONN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Two Sigma Securities's SONN Position: Q3 2023 in Review

Two Sigma Securities sold out of Sonnet BioTherapeutics (SONN) in Q3 2023, closing a stake of 387 shares — an estimated $33.4K sold.

Two Sigma Securities first reported a position in SONN in Q3 2021 and held it in 7 quarters. The position peaked at $45K in Q1 2022. 9 funds tracked by Wall St. Rank hold SONN as of Q3 2023.

  • Two Sigma Securities reported no remaining Sonnet BioTherapeutics position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Securities sold 387 Sonnet BioTherapeutics shares in Q3 2023, an estimated $33.4K.
  • Two Sigma Securities first reported a position in Sonnet BioTherapeutics in Q3 2021 and held it in 7 quarters.
  • Two Sigma Securities's Sonnet BioTherapeutics position peaked at $45K in Q1 2022.
  • 9 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.